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ABSTRACT: Electrophysiological testing remains an important efficacy
parameter in clinical neuropathy trials. The quality of nerve conduction stud-
ies in reported trials varies greatly, and may be responsible for negative
results. We report the utilization of an expert core lab for electrophysiological
testing. With the core lab, the variability of repeat testing is comparable to
that of a single, excellent laboratory. Motor conduction velocities demon-
strated a coefficient of variation of 3% and sensory conduction velocities 4%
across 60 study sites. The distal motor evoked potential amplitudes varied
by 13% at the ankle, and 10% at the wrist. The sensory potential amplitudes
varied by 16% at the ankle, and 11% at the wrist in 60 sites. The overall
monitoring rate in all submitted nerve conduction tracings was 36.6%. Our
results show that an expert core lab can improve the electrophysiological
quality of clinical trial data with the potential to show small changes in nerve
conduction velocities and in both motor and sensory potential amplitudes.
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Electrophysiological testing (nerve conduction
studies, NCS) remains an essential technique for
quantifying peripheral nerve function in peripheral
neuropathy trials due to its inherent reliability, re-
producibility, and objectivity.4,6–9 Nerve conduction
studies measure peripheral nerve function directly
without subjective bias and without contamination
by central nervous system pathways. In research tri-
als, neuropathy is defined currently on the basis of
two out of five possible areas of abnormality: symp-
toms, signs, NCS, quantitative sensory testing (QST),
and autonomic tests.2 The least variable and most
reliable is the NCS.10 In addition, regulatory bodies
have stated the requirement of more than one pa-
rameter showing positive change in order to accept
a compound’s efficacy. Clinical measures of symp-
toms and signs as used routinely are highly variable.
Quantitative clinical scales have been developed, but
are cumbersome, and not widely employed as they
too are variable, particularly for symptoms.7 QST has
drawbacks as to reliability, reproducibility, and site
of pathology.11,12
In early studies, uncontrolled nerve conduction
evaluations were undertaken. Those responsible for
analyses had little appreciation of the technical limi-
tations of electrophysiology. A high degree of vari-
ability in parameters was observed: a much greater
degree than repeat studies in a single laboratory.3,10
Consequently, the power of these studies to detect
any meaningful change was severely limited.10 An
advance in NCS was the institution of a central ex-
pert monitoring facility to provide quality control of
the nerve conduction studies. The expert reviewer
improved the variability of repeat measures and the
power of studies. This function was still limited in its
ability to evaluate data, and ensure rigorous protocol
adherence and technical competence.
We report a method of optimizing electrophysi-
ological testing in large-scale, multicenter trials. The
reproducibility of NCS achieved in 60 sites is that
observed in a single, excellent laboratory when strict
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adherence to study protocols is carried out, and
when an expert core lab is used to monitor all the
electrophysiological data.
MATERIALS AND METHODS
As part of a large-scale diabetic polyneuropathy trial
involving 60 centers in Europe and North America, a
core lab was set up at The Toronto Hospital by an
experienced electromyographer and neurologist
(VB) to evaluate electrophysiological tracings ob-
tained on patients in this study. The core lab devel-
oped the protocol for electrophysiological testing to
be used by all centers. The core lab reviewed the
qualifications of all electrophysiologists and techni-
cians at each study site. In order to participate in this
trial, the electrophysiologist was required to be a full
member of the American Association of Electrodiag-
nostic Medicine, or have equivalent training and cre-
dentials. All patients had screening nerve conduc-
tion studies, then triplicate measurements at the
beginning of the study and after 12 months. The
patients all had a standard battery of nerve conduc-
tion studies including: peroneal motor, bilateral
surals, median motor, and sensory. The curves were
faxed or couriered to the core lab, where they were
entered into a database. A 1-cm scale was attached to
each tracing to judge any distortion in faxed trac-
ings. If the signal was distorted, the tracings were
then couriered to the core lab. All identifying infor-
mation as to site, date of testing, investigator, and
patient name was eliminated, and a random number
assigned to the curve. The information was recorded
in a Filemaker Pro database for the Macintosh sys-
tem. The curves were assessed in a blinded fashion
by an electromyography (EMG) technician, then by
a second EMG technician, as to adherence to proto-
col (side tested, baseline-to-peak amplitudes, onset
latencies, temperature control, averaging of sensory
potentials) and quality of tracing (flatness of base-
line, motor contamination of sensory potentials,
similarity of motor curves with different sites of
stimulation along the same nerve, and accuracy of
calculations). After this review and acceptance of the
tracings, the case report forms were completed by
the core lab. If the curves failed to meet protocol
requirements, corrections were made on the curve
(e.g., correcting latency measurement from the peak
to curve onset, or amplitude from peak-to-peak to
baseline-to-peak), the site was asked for any missing
information (e.g., side tested, distance, tempera-
ture), or the site was asked to repeat the tracing in
cases of excessive artifact. After review and accep-
tance, all curves for 1 patient for 1 day’s nerve con-
duction studies were reassembled, and reviewed for
a final time. At this point, some additional aberra-
tions were discovered: e.g., identical curves submit-
ted for two different days, wrong side tested on a
nerve, a leg changing length by 20 cm in 1 day. The
site would be asked to provide correct data, or repeat
the tracing. The core lab sent reports to each site on
each set of nerve conduction tracings, and the data
were sent to a double-data-entry facility. The com-
pleted case report forms were sent to each site.
Prior to randomizing patients in the study, each
site completed 4 normal subjects twice to familiarize
the sites with the protocol, and the procedures.
Training meetings were held with groups of investi-
gators to review in a minute fashion the protocol and
standard operating procedures. Each site was pro-
vided with a standard operating manual (SOM) of
the nerve conduction and reporting procedures.
Each site was monitored by Hoffmann-LaRoche
(HLR) staff, and if necessary, the core lab performed
site audits.
Sites were standardized with respect to back-
ground and training of personnel prior to starting
the study. The SOM outlined all core lab proce-
dures, NCS procedures, and gave examples of poor
waveforms.
Testing was standardized as to temperature, side
of testing, stimulation protocol, averaging sensory
potentials, marking latencies and amplitudes, and
providing information for the core lab. Repeat test-
ing could be done on consecutive days, but not
sooner. Prior to randomization of patients to active
treatment, all nerve conduction studies had to be
approved and accepted in the placebo run-in base-
line. All reviews were blinded. To maintain quality
assurance, an external laboratory reviewed a sub-
sample of the tracings, and provided opinions as to
the actions taken by the core lab.
Compliance of the sites with the core lab activi-
ties was integral to the study and participation in the
trial as mandated by HLR and supported for the
duration of the trial. All sites agreed to these proce-
dures prior to starting the study.
The core lab maintained a detailed standard op-
erating procedure on site, and underwent auditing
by HLR personnel twice during the trial to ensure
strict compliance with protocol procedures.
We examined the mean values and variability of
repeat testing for all study centers, and then for geo-
graphic areas (Canada, Europe, and the U.S.). Sta-
tistical analyses were done using Statview 4 for the
Macintosh. We computed means ± standard errors
for normative subjects, means ± standard deviations
for patients, and coefficients of variation as a per-
centage for repeat testing.
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RESULTS
Sixty sites participated in the trial. Compliance with
core lab functions was ensured by the sponsor of the
program (HLR), who was committed to the core lab
concept. Most sites accepted the concept readily, al-
though full compliance from every site required ex-
tensive discussion and education as the value of con-
sistency and standardization across all sites.
The core lab screened data from 1474 patients
recruited at 60 sites. Thirteen sites were in Canada
(495 patients), 16 in Europe (285 patients), and 31
were in the U.S. (565 patients). Of these patients,
1345 were randomized and continued with the trial
and 1144, or 85%, completed the trial.
NCS in 253 normal subjects were done twice in
1–3 months. The recruitment interval extended over
9 months. The study interval was 12 months. Fifty-
seven normal subjects had repeat testing at the end
of the double-blind interval. Turnaround time of the
blinded review required 6 working days due to the
blinding of the review process and the high volume
of nerve conduction studies which arrived in the
core lab daily at the peaks of recruitment and
completion (up to 50 sets, or 350 individual nerves).
Our methodology was unique in that the review pro-
cess was completely blinded, and the curves were
reread, and measurements redone, if needed, to
comply with protocol requirements. In essence, all
data were centralized.
Patients were selected for mild neuropathy as
shown by the values of the nerve conduction param-
eters in the control subjects and patients with dia-
betic polyneuropathy (Table 1). Many values fall
within the lower range of normal. In addition, no
significant change in conduction velocities or ampli-
tudes were observed over a 12-month study interval,
in either placebo- or drug-treated patients in this
trial. This indicates that at this early stage of neurop-
athy, very little, if any, deterioration in electrophysi-
ology occurs in 12 months.
The variability of repeat testing is shown in Table
2, with a breakdown for different nerves. At baseline,
the variability was 13% for peroneal motor ampli-
tude at the ankle, and 15% at the knee. For median
motor, the amplitude variability was 10% at the wrist
and 11% at the elbow. The numbers were slightly
lower at the completion of the study. The motor
nerve conduction velocities varied by only 3% in arm
and leg across 60 sites at baseline and completion.
More striking is the variability of sensory studies.
Sural conduction velocities varied by 5% at the on-
set, and 4% at the study termination. Median nerve
sensory conduction varied by 4%. The sural sensory
amplitudes varied by 16% at onset and 15% at the
termination, and median sensory amplitudes varied
by 11% at the wrist and 17% at the elbow throughout
the study.
The Canadian sites had the lowest variability in




n 253 1345 1144
Median motor DL 3.3 ± 0.03 4.0 ± 0.9 4.1 ± 0.8
Median motor amp wrist 10.4 ± 0.2 8.2 ± 2.7 8.4 ± 2.7
Median motor amp elbow 9.7 ± 0.2 7.5 ± 2.7 7.8 ± 2.6
Median motor CV 58.5 ± 0.3 51.2 ± 4.7 51.0 ± 4.5
Median sensory DL 2.5 ± 0.02 3.1 ± 0.6 3.1 ± 0.7
Median sensory amp wrist 37.5 ± 1.05 15.4 ± 9.4 15.3 ± 9.3
Median sensory distal CV 58.1 ± 0.4 47.6 ± 8.0 47.4 ± 7.9
Median sensory amp elbow 17.5 ± 0.6 7.1 ± 4.3 7.0 ± 4.3
Median sensory proximal CV 62.9 ± 0.3 55.0 ± 5.0 54.8 ± 4.8
Peroneal motor DL 4.3 ± 0.04 4.9 ± 1.1 4.9 ± 1.0
Peroneal motor amp ankle 6.2 ± 0.1 4.0 ± 2.2 4.0 ± 2.3
Peroneal motor amp knee 5.7 ± 0.1 3.5 ± 2.0 3.5 ± 2.1
Peroneal motor CV 48.9 ± 0.2 40.4 ± 5.0 40.2 ± 5.1
Right sural DL 2.9 ± 0.02 3.3 ± 0.6 3.3 ± 0.5
Right sural amp 14.8 ± 0.4 5.5 ± 3.8 5.5 ± 3.9
Right sural CV 49.0 ± 0.3 41.7 ± 5.9 42.0 ± 5.8
Left sural DL 2.9 ± 0.02 3.3 ± 0.6 3.3 ± 0.5
Left sural amp 15.1 ± 0.5 5.6 ± 3.9 5.5 ± 4.0
Left sural CV 48.8 ± 0.3 41.8 ± 5.9 41.8 ± 5.9
DL, distal latency (ms); amp, amplitude (motor, mV; sensory, µV); CV, conduction velocity (m/s). Values for control subjects are expressed as
arithmetic means ± standard error; values for patients are expressed as arithmetic means ± standard deviation.
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the trial, as shown in Table 3. For motor amplitudes
the variability in Canadian patients was 11% at onset,
compared to 9% at termination for distal peroneal,
and 8% and 7% for distal median. The motor con-
duction velocities were 3% for both. Sural nerve con-
duction velocities varied by 4% in Canada through-
out the trial, and the amplitudes by 13% at onset and
by 11% and 10% at termination. Similar values were
found for median nerve sensory activity.
The rejection and query rate was lowest for
Canada with an absolute rejection rate of 4% at base-
line, compared to 11% for both Europe and the U.S.
The overall rejection rate was 8.7% at baseline. The
correction rate was 22.6% for Canada, 38.4% for Eu-
rope, and 31.4% for the U.S. An overall rate of
29.6% was found at entry of patients. In summary,
the core lab had comments, corrections, or rejec-
tions on fully 38.2% of all nerve conduction study
tracings submitted to the core lab. All sites improved
at completion of the trial. The rejection rates were
lower: overall 6.3% for the study, 2.8% for Canada,
9.6% for Europe, and 7.9% for the U.S. The correc-
tion rate was 27.9% overall, 14.1% in Canada, 41.4%
in Europe, and 32.8% in the U.S. Overall, the core
lab had comments, corrections, or rejections on
34.3% at completion. The overall number of tracings
with some change in the trial was 36.6%, or 3300 of
9021 individual nerve tracings.
Concordance with the external monitoring facil-
ity was extremely high at about 95% agreement on
actions between the two facilities. Disagreements
most often concerned review of isolated tracings by
the external laboratory, and were resolved when all
repetitions of the same nerve conduction study were
available for assessment.
DISCUSSION
Electrophysiological testing is an efficacy parameter
in widespread use and is the most reliable quantita-
tive method currently available to study nerve func-
tion in polyneuropathy. The method is limited by
the variability of repeat testing, which is large in re-






n 253 1345 1144
Median motor DL 4 4 4
Median motor amp wrist 7 10 9
Median motor amp elbow 8 11 10
Median motor CV 3 3 3
Median sensory DL 4 4 4
Median sensory amp wrist 8 11 11
Median sensory distal CV 3 4 4
Median sensory amp elbow 13 17 17
Median sensory proximal CV 3 4 3
Peroneal motor DL 5 6 6
Peroneal motor amp ankle 9 13 12
Peroneal motor amp knee 10 15 13
Peroneal motor CV 3 3 3
Right sural DL 5 6 6
Right sural amp 10 16 15
Right sural CV 3 5 4
Left sural DL 4 6 5
Left sural amp 10 16 15
Left sural CV 3 5 4
DL, distal latency (ms); amp, amplitude (motor, mV; sensory, µV); CV,
conduction velocity (m/s). Values are expressed as percentages.
Table 3. Geographic variability of repeat testing.
Parameter
Baseline Completion
All CAN EUR USA All CAN EUR USA
n 1345 285 565 1144 442 239 463 495
Median motor amp wrist 10 8 12 11 9 7 11 10
Median motor amp elbow 11 8 13 13 10 7 12 11
Median motor CV 3 3 4 4 3 3 3 3
Median sensory amp wrist 11 10 13 12 11 10 11 12
Median sensory distal CV 4 4 4 4 4 3 4 4
Median sensory amp elbow 17 15 18 19 17 15 18 19
Median sensory proximal CV 4 4 4 4 3 3 4 4
Peroneal motor amp ankle 13 11 15 15 12 9 14 14
Peroneal motor amp knee 15 12 16 16 13 11 15 15
Peroneal motor CV 3 3 4 4 3 3 4 4
Right sural amp 16 13 18 17 15 11 17 17
Right sural CV 5 4 5 5 4 4 4 5
Left sural amp 16 13 19 17 15 10 17 16
Left sural CV 5 4 5 5 4 4 4 5
All, total patient population; CAN, Canadian patients; EUR, European patients; USA, American patients; Amp, amplitude; CV, conduction velocity.
Values are expressed as percentages.
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ported multicenter trials.4,13 For this reason, conduc-
tion velocity alone has been the major end point,
and amplitude measures have not been used in the
past, although they are being used now.1 With our
methods of using a core lab for quality control, of
generating data centrally, of maintaining adherence
to protocol and excellence of technique, we
achieved a degree of variability in nerve conduction
studies in 60 centers previously observed only in
single excellent laboratories.5 This low variability was
universal: motor and sensory nerve conduction ve-
locities and amplitudes in upper and lower limbs.
Motor nerve conduction velocities showed the least
variability (3%). The sensory nerve conduction ve-
locities varied between 3 and 5%. Amplitudes had
greater variability, with upper limb motor ampli-
tudes varying up to 10%, and those in the leg up to
15%. Sensory potential amplitudes in the leg had up
to 16% variability, and the arm distally 11%, but 17%
at the elbow. These values across 60 sites are the
same as observed in a single excellent laboratory.5
The requirement for blinding is not absolute, but
does eliminate any possibility of bias in the review
process. Unblinded review would require much less
time in the core lab, as paper handling would be
greatly reduced, although bias in monitoring could
be claimed.
Despite efforts by all centers to follow protocol
requirements in the manner dictated by this study,
our overall 36.6% rate of intervention indicates the
absolute need for an experienced, insightful, and
knowledgeable core lab, and for sponsor commit-
ment to the core lab principle.
Variability in 60 sites can be the same as that of a
single excellent laboratory using these methods.
Consequently, the number of patients required to
show small changes (as expected in nerve conduc-
tion velocity) is not as great, and the ability to show
some change in amplitude is present. Studies with
fewer patients would be powered to show these re-
sults. This study had the power to show a change of
0.2 m/s in conduction velocity between treatment
groups and a 0.4-µV change in amplitude, neither of
which occurred.
We believe this level of variability can be achieved
in any multicenter trial, and that this methodology
sets a new standard for electrophysiological testing
in clinical trials in any polyneuropathy.
We noted some regional differences in variability
of testing and query rates, as shown in Tables 3 and
4, but overall the 60 sites showed excellent compli-
ance with protocol and study procedures, although
the rejection/query rates remained above 30% for
the entire trial, confirming the utility of a core lab.
Finally, the lack of change in conduction velocity
or amplitude over 12 months is in concordance with
the results of the Statil trial done in a similarly af-
fected population of patients for 18 months.13 This
suggests that the decline in nerve conduction veloc-
ity and amplitude in diabetic polyneuropathy are not
necessarily a linear function of time in early neurop-
athy, and that these parameters may be static during
this phase of diabetic polyneuropathy. This finding
has implications for trials in which halting of definite
deterioration is required to show the efficacy of a
treatment. It may be that a more advanced popula-
tion needs to be studied if decline in NCS in 12
months is essential to show efficacy, since other stud-
ies have shown decline in more affected individuals
at entry. The pattern of decline over years is uncer-
tain, as few studies have followed NCS in patients
annually from diagnosis, and our study was not a
natural history trial. Limiting trials to mildly affected
patients may limit any electrophysiological efficacy
that can be demonstrated in 12 months. If only
mildly affected individuals are likely to benefit from
a therapy, then a requirement for lengthy 5–10-year
trials may be present.
In summary, we present the value of core moni-
toring laboratories for electrophysiological monitor-
ing in clinical trials. Utilization of such laboratories
increases the power of studies which use nerve con-
duction studies as an efficacy parameter, allows,
fewer patients to be studied, and provides the poten-
Table 4. Rejection and query rates.
Parameter
Baseline Completion
All CAN EUR USA All CAN EUR USA
Visits accepted 61.8 73.3 50.3 57.4 65.7 83.1 48.8 59.3
Visits accepted with correction 29.6 22.6 38.4 31.4 27.9 14.1 41.4 32.8
Visits rejected 8.7 4.1 11.2 11.2 6.3 2.8 9.6 7.9
Monitoring rate 38.2 26.7 49.7 42.6 34.3 16.9 51.0 40.7
Visit = one complete set of 6 or 7 nerve conduction tracings. The number of interventions per set of tracings is not listed, and varied from 1 to 10. All,
total patient population; CAN, Canadian patients; EUR, European patients; USA, American patients. Values are expressed as percentages. Monitoring
rate = % of tracings requiring intervention.
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tial to detect small differences in amplitude and con-
duction velocity. Our results set a new standard in
electrophysiological testing in multicenter trials.
THE ROCHE NEUROPATHY STUDY GROUP
The Roche Neuropathy Study Group comprises 60
study sites. The listing shows principal investigator,
electromyographer/neurophysiologist (if different
from principal investigator), city, and country in al-
phabetical order: A. Belanger, L. Cote, Montreal,
Canada, T. Benstead, L.P. Heffernan, Halifax,
Canada, R. Bergenstal, F. Taylor, Minneapolis, USA,
R. Bernstein, R. Miller, San Francisco, USA, F.W.
Bertelsmann, R.L.M. Strijers, Amsterdam, The Neth-
erlands, A. Boulton, W. Schady, A. Carrington,
Manchester, U.K., V. Bril, Toronto, Canada, D. Bru-
net, Quebec City, Canada, W. Carter, J. Nickols, S.
Rudnicki, Little Rock, USA, A. Charles, A. Starr, Y.
Zhu, Irvine, USA, D. Clarke, D. Smith, Salt Lake City,
USA, V. Cwik, Edmonton, Canada, S. DeCherney, R.
Fisher, Newark, USA, S. Dippe, R. Goodell,
Scottsdale, USA, J. Dupre, I. Hramiak, London,
Canada, C.J.V. Fox, A. Bissessar, Northampton, U.K.,
R. Freeman, Boston, USA, C. Godin, A. Lamontagne,
Sherbrooke, Canada, R. Goldberg, K. Sharma, M.
Kato, Miami, USA, D.A. Greene, E. Feldman, Ann
Arbor, USA, G. Grunberger, J.F. Selwa, Detroit, USA,
Y. Harati, C. Gooch, R. Kolimas, Houston, USA, K.
Hermansen, J. Christensen, V. Nielson, Aarhus, Den-
mark, J. Hilsted, M. Damholt, L.B. Blatt, Hvidovre,
Denmark, I. Ipp, T. Anderson, Torrence, USA, P.
Jennings, C.K. Laljee, York, U.K., J. Jervell, E. Jorum,
T. Ganes, Oslo, Norway, F. Kennedy, W. Litchy,
Rochester, MN, USA, C. Kilo, R. Frere, B. Green, St.
Louis, USA, G. King, J. Rosenszweig, A. Herzog, Bos-
ton, USA, V. Koivisto, A.M. Seppalainen, Helsinki,
Finland, D. Lau, P. Bourque, D. Preston, Ottawa,
Canada, S. Levin, S.A. Chrissian, Los Angeles, USA,
A. MacCuish, P. Jamal, Glasgow, U.K., J.I. Malone, J.
Korthals, Tampa, USA, L. Olansky, W.D. Shipley,
Oklahoma City, USA, M. Pfeifer, J. Farquhar, Spring-
field, IL, USA, N. Pillay, Winnipeg, Canada, D. Porte,
Seattle, USA, G. Poticha, S. Gulevich, Denver, USA,
P. Raskin, R. Greenlee, Dallas, USA, G. Rayman, S.J.
Wroe, Suffolk, U.K., J. Rosenstock, F. Gul, Dallas,
USA, C. Saudek, D. Cornblath, Baltimore, USA, J.
Scarpello, P. Heath, Staffordshire, U.K., A. Scheen,
J.M. Crielaard, F.C. Wang, Liege, Belgium, J.
Schoelmerich, B. Zietz, Regensberg, Germany, A.
Schuaib, P. Siemens, Saskatoon, Canada, P. Shee-
han, T. Herron, Westlake, USA, J. Skyler, C. Vande-
nakker, Miami, USA, D. Studney, Vancouver,
Canada, M. Swenson, San Diego, USA, M. Uusitupa,
J. Partanen, E. Mervaala, Kuopio, Finland, A. Vinik,
M. Holland, Norfolk, USA, J. Wales, I. Smith, Leeds,
U.K., D. Zieglar, R. Piolot, Dusseldorf, Germany, D.
Zochodne, Calgary, Canada.
Professor J. Arezzo is acknowledged for unstinting advice and
encouragement during the trial and in the manuscript prepara-
tion. Contract grant sponsor: Hoffmann-LaRoche.
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